The murine IgM anti-T12/CD6 mAb has been used experimentally in vivo as an anti-T-cell agent in MS, leukaemia, in acute graft-versus-host GvH disease, and in acute renal transplant rejection [3, 4, 72]. This evidence concerns the gene CD6 and myeloid sarcoma.